Company profile: Propagenix
1.1 - Company Overview
Company description
- Provider of healthcare technology platforms for translational biomedical research, including EpiX technology to expand primary epithelial cells without genetic modification, CR feeder-cell culture to replicate epithelial cells, engineered bi-layered skin constructs, airway epithelium models and theranostic assays, and collaborative and sponsored research for drug discovery and toxicology screening.
Products and services
- CR Technology: A cell culture-grade feeder-cell based method that achieves extensive replication of diverse primary epithelial cells while preserving biological characteristics for translational research and tissue model development
- Engineered airway epithelium models and theranostic assays: Custom-engineered systems that develop differentiated mucociliary epithelium from expanded airway epithelial cells for research and therapeutic applications in drug discovery and toxicology screening
- EpiX Technology: A research-grade cell culture platform enabling significant expansion of primary epithelial cells without genetic modification, maintaining genomic integrity for translational research and tissue models in drug discovery and toxicology screening
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Propagenix
Altor BioScience
HQ: United States
Website
- Description: Provider of immunotherapeutic agents for cancer, viral infections, and autoimmune diseases, including ANKTIVA (N‑803), an IL‑15 receptor agonist for non‑muscle invasive bladder cancer; investigational cancer and viral therapies and vaccines (personalized neoepitope-based, HIV, HPV); Tri‑Ad5 vaccine for Lynch syndrome; STAR Fusion reagents for diagnosis/targeting, STAR Multimer reagents for research; and clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Altor BioScience company profile →
Talecris
HQ: Spain
Website
- Description: Provider of plasma-derived protein therapies, produced and marketed by a biopharmaceutical company founded in 2004 and based in Barcelona, Spain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Talecris company profile →
Lin Bioscience
HQ: Taiwan
Website
- Description: Provider of innovative drug therapies addressing unmet medical needs, developing: LBS-008, an oral treatment for dry age-related macular degeneration and Stargardt disease; LBS-007, a CDC7 inhibitor for leukemia and solid tumors; LBS-002, an anti-tubulin therapy for brain tumors that crosses the blood-brain barrier; and LBS-009, an oral therapy for NAFLD and type 2 diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lin Bioscience company profile →
Futura Medical
HQ: United Kingdom
Website
- Description: Provider of proprietary transdermal solutions. Products include Eroxon, a topical gel for erectile dysfunction that helps men achieve an erection within 10 minutes without a prescription, and DermaSys, a patented platform for delivering treatments via the skin tailored to specific therapeutic indications and desired speed of onset and duration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Futura Medical company profile →
Animol Discovery
HQ: United States
Website
- Description: Provider of a drug discovery platform combining DNA-encoded chemical libraries, AI/ML, and computational chemistry to rapidly identify novel veterinary medicines; focuses on discovering and developing small-molecule drugs for companion and farm animals addressing infectious and chronic diseases, with a proprietary pipeline of veterinary small molecules including next-generation antiparasitics and therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Animol Discovery company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Propagenix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Propagenix
2.2 - Growth funds investing in similar companies to Propagenix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Propagenix
4.2 - Public trading comparable groups for Propagenix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →